1. Introduction {#sec1-1}
===============

The higher incidence of non-communicable diseases, notably diabetes and hypertension, has lead to an increase in the number of CKD patients. In the US, 25.8 million people have Diabetes (8.3% of the US population) ([@ref56]). Diabetes is the leading cause of Chronic Kidney Disease (CKD) in developed countries. It is estimated that 15-20% of type 1 diabetes patients and 30-40% of type 2 diabetes patients will develop end stage renal disease ([@ref3]). In Malaysia, Diabetes is the leading cause of CKD contributing to 58% of all new patients requiring dialysis in 2012 ([@ref35]). Although CKD remains asymptomatic till late stage, the progressive renal function decline during the course of diabetic nephropathy can be detected early when renal function is still normal or elevated ([@ref64]). Early diagnosis is important for kidney disease patients as it is a source of considerable morbidity and mortality. The most widely used definition of CKD is by the National Kidney Foundation's Kidney Disease Outcome Quality Initiative stating Glomerular Filtration Rate (GFR) \<60ml/min/1.73m^2^ that is present for 3months or more; or evidence of kidney damage for 3 months or more with or without decreased GFR as evidenced by any of the following: Microalbuminuria, Macroalbuminuria, Proteinuria, Glomerular Haematuria, Pathological abnormalities, Anatomical abnormalities ([@ref34].). Screening for kidney function includes Glomerular Filtration Rate (GFR) and Albuminuria ([@ref42]; [@ref44]; [@ref46]). In the US and many parts of Europe the GFR is automatically reported when serum creatinine is ordered, this however is not the case in Malaysia. Screening for CKD in Malaysia includes a urine test for albuminuria and a blood test for serum creatinine. The aim of this review is to discuss the strengths and limitation of CKD screening methods and its application in Malaysia, a multiethnic Asian population.

2. Methodology {#sec1-2}
==============

2.1 Design and Selection Methods {#sec2-1}
--------------------------------

This is a review of the literature on current CKD screening practices. A systematic search of the literature was carried out and data were retrieved from Google Scholar, Pubmed Central, Scopus and Science Direct. The keywords used were Albuminuria, Chronic Kidney Disease (CKD), Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), Creatinine, Cystatin C, Glomerular Filtration Rate (GFR). The Search was limited to studies published in the English language for the period between 2000 and 2014. The search included cross-sectional and longitudinal studies carried out among the general population and CKD patients with or without diabetes. The search identified a total of 2040 studies of which 38 studies were selected by the Authors as relevant to the subject under investigation and met the preset inclusion criteria. All 38 studies were carried out in Asian and western countries.

2.2 Selection Criteria {#sec2-2}
----------------------

### 2.2.1 Albuminurea {#sec3-1}

The search for albuminuria identified a total of 866 articles. The selection criteria are:

(1)Cross-sectional studies among diabetic patients who underwent screening for kidney function. Only studies that have reported the number of diabetic patients with GFR \<60ml/min/1.73m^2^ and normal albuminuria were selected. Six articles met the criteria.(2)Longitudinal studies carried out among diabetic patients with and without albuminuria. Studies that reported the course of albuminuria at the end of the study period were selected. Six studies met the criteria.

### 2.2.2 GFR {#sec3-2}

The search for GFR equation identified 216 articles. The selection criteria are:

(1)Longitudinal studies among patients with and without diabetes in which the GFR was estimated using the MDRD equation and the CKD-EPI equation. Studies that compared both equations in terms of risk stratification and CKD prevalence were selected. Five articles met the criteria.(2)Cross sectional studies among patients with a wide range of GFR who underwent GFR estimation using the MDRD equation and the CKD-EPI equation. Studies that compared the performance of both equations in terms of bias and accuracy were selected. Six articles met the criteria.

### 2.2.3 Cystatin C {#sec3-3}

The search for cystatin C identified 958 articles including patients with and without CKD. The selection criteria are cross-sectional studies among CKD patients in which serum cystatin C was measured. Studies that compared serum cystatin C with serum creatinine for detecting renal disease were included. Thirteen articles met the criteria.

2.3 Data Extraction {#sec2-3}
-------------------

The following variables were extracted from the selected studies, study design, population charecteristics, number of participants, number of years of follow up, estimated and measured GFR (when applicable), percentage of patients with normal albuminuria, percentage of patients with microalbuminuria, prevalence of CKD and number of CKD patients reclassified using the CKD-EPI equation.

3. CKD Screening in Malaysia {#sec1-3}
============================

The prevalence of diabetes and its risk factors continue to rise at an alarming rate. From 1996 to 2006 Malaysia witnessed a 250% increase in the prevalence of Obesity and 88% increase in prevalence of diabetes ([@ref57]). Recently the prevalence of diabetes among adults age 18 years and above in Malaysia is reported at 15.2% ([@ref58]). Uncontrolled diabetes can lead to complications. CKD is one of the long term complications of diabetes. In Malaysia, diabetes is the leading cause of CKD contributing to 58% of all new patients requiring dialysis in 2012([@ref95]). This has considerable public health implication considering the morbidity and high cost associated with the disease. The prevalence of CKD in Malaysia is currently reported at 9.07% ([@ref24]). It is recommended that screening for CKD is initiated at the time of diagnosis of type 2 diabetes and 5 years after the diagnosis of type 1diabetes. Screening includes assessment of proteinuria, heamaturia and renal Function ([@ref9]). Screening is carried out annually for diabetic and hypertension patients. Screening for CKD is also recommended for patients at high risk of CKD. Screening for albuminuria is carried out using urine dipstick. This test is cheap, convenient and widely available. In diabetic patients, urine albumin: creatinine ratio (ACR) in an early morning urine sample should be performed annually if urine dipstick is negative. Microalbuminuria is defined as ACR 2.5-30 mg/mmol for males and 3.5-30 mg/mmol for females. Due to non renal factors affecting albumin level in urine, repeat tests are carried out within three to six months. When 2 out of 3 tests are positive then patient is diagnosed with diabetic nephropathy. Renal function will be assessed by estimated GFR using the Modification of Diet in Renal Disease (MDRD) equation. Staging of CKD is based on KDIGO 2002 ([@ref4]). Other tests such as renal imaging or biopsy are carried out when deemed necessary. Currently, it is not a common practice for laboratories in Malaysia to report an estimated GFR when renal profile or serum creatinine is ordered by physicians. In practice, serum creatinine is used by clinicians to determine the presence or absence of CKD despite its known limitation ([@ref7]). A recent study carried out at primary care setting in Malaysia showed that using serum creatinine instead of estimated GFR to detect CKD fail to detect a third (35.5%) of patients with renal impairment who had seemingly normal serum creatinine ([@ref7]). This is similar findings to another study carried out in Spain that found that estimated GFR identified an additional 13.4% of diabetic patients with renal impairment who would have been missed if only serum creatinine was measured([@ref11]). The following sections will discuss albuminuria and GFR as two principle methods for CKD screening. In addition, cystatin C will be discussed as a new potential marker for CKD screening.

4. CKD Screening Methods: Strength and Limitation {#sec1-4}
=================================================

4.1 Albuminuria {#sec2-4}
---------------

The clinical picture of diabetic kidney disease has been characterized by the presence of albuminuria prior to the decrease in GFR. Screening for albuminuria is cheap, convenient and widely available. Microalbuminuria refers to the increase passage of albumin through the glomeruli. The mechanism for the development of microalbuminuria is complex and involves changes in glomerular pressure (or filtration) in addition to changes to glomeruli structure ([@ref77]). Screening for albuminuria is one of the primary methods to detect kidney disease ([@ref42]; [@ref64]; [@ref46]; [@ref90]). It should be carried out at least once a year for diabetic patients. Albumin excretion can increase transiently due to non-renal factors as well, such as urinary tract infection, fever, exercise, congestive heart failure and hyperglycemia ([@ref46]). Due to this variation, microalbuminuria is confirmed if at least 2 of 3 tests (performed within minimum of 3 months) are positive. Microalbuminuria is defined by an albumin excretion (AER) between 20-200 µ/min (30-300 mg/24 hours), this amount cannot be detected by urine dipstick. Proteinuria, also known as macroalbuminuria is defined as AER exceeding 200 µ/min (300 mg/24 hours). Macroalbuminuria is associated with decline in GFR and rise in Blood pressure([@ref5]). The GFR in people with type 2 diabetes typically begins to decline in the late microalbuminuric stage and, without intervention declines at an average rate of 8-12 ml/min/1.73m^2^/year ([@ref4]). However, the classical picture of albuminuria prior to declining GFR has been challenged recently. Growing evidence suggests that not all diabetic patients will present with the typical albuminuria findings and that CKD may be accompanied, rather than preceded by microalbuminuria, or it may even develop in those with albuminuria levels that revert to normal ([@ref21]). The reason for this variation is not clear. Several studies indicate that up to 30% of people with type 2 diabetes and a GFR \<60ml/min/1.73m^2^ have normal albuminuria ([@ref1]; [@ref40]; [@ref39]). Patients with normal albuminuria and renal impairment were found to be older, had lower prevalence of obesity, lower diastolic blood pressure, lower prevalence of smoking, macrovascular disease and ischemic heart disease and lower HBA1c ([@ref11]). A recent study found that among diabetic patients with renal impairment (estimated GFR less than 60/ml/min/1.73m^2^), 56.6% had normal albuminuria, 30.8% had microalbuminuria and 12.6% had macroalbuminuria ([@ref62]). [Table 1](#T1){ref-type="table"} shows the prevalence of normal albuminuria among kidney disease patients in similar studies ([@ref39]; [@ref60]; [@ref62]; [@ref71]; [@ref89]; [@ref96]). This matter was put to the test when several cohort studies looked into the course of microalbuminuria in diabetic patients and serial measurements of albuminuria revealed that a number of microalbuminuric patients reverted to normal albuminuria, see [Table 2](#T2){ref-type="table"} ([@ref64]; [@ref66]; [@ref85]; [@ref19]; [@ref26]; [@ref65]). Growing evidence show that GFR decline can occur in patients with normal albuminuria ([@ref31]). This could suggest that albuminuria may not be as sensitive as a marker for kidney function decline as previously thought. Further studies should be carried out in Malaysia to determine the role of albuminuria in detecting a decline in kidney function and whether the absence of albuminuria in CKD patients is related to the use of angiotensin converting enzyme inhibitors. This will help Clinicians to make an informed decision when screening patients for CKD.

###### 

The prevalence of Normal Albuminuria in CKD Patients

  1^st^ Author   Study Population   Patients with GFR \< 60ml/min   Percentage of patients with GFR\<60ml & normal albuminuria
  -------------- ------------------ ------------------------------- ------------------------------------------------------------
  ([@ref39]      Type 2 diabetes    171                             30%
  ([@ref60]      Type 2 diabetes    2546                            17%
  ([@ref71]      Type 2 diabetes    1132                            51%
  ([@ref96]      Type 2 diabetes    506                             51.7%
  ([@ref89]      Type 2 diabetes    920                             55%
  ([@ref62]      Type 2 diabetes    2959                            56.6%

###### 

The course of Microalbuminuria in diabetic patients

  1^st^ Author   Study Population    Follow up period(years)   Patients with Microalbuminuria   Progressed to Macroalbuminuria   Regress to Normal
  -------------- ------------------- ------------------------- -------------------------------- -------------------------------- -------------------
  ([@ref85]      Diabetic patients   7                         At start of follow up 23         6%                               56%
                                                                                                                                 
  ([@ref66]      Type 1 diabetes     8                         386                              19                               58
                                                                                                                                 
  ([@ref19]      Type 1 diabetes     7                         351                              13.9%                            50.6%
                                                                                                                                 
  ([@ref26]      Type 1 diabetes     7,5                       79                               34%                              35%
                                                                                                                                 
  ([@ref64]      Type 1 diabetes     8-12                      At start of follow up 301        31%                              35.58%
                                                                                                                                 
  ([@ref65]      Type 1 diabetes     12                        79                               27                               39

4.2 Serum Cystatin C {#sec2-5}
--------------------

Cystatin C is a 13 kDa protein filtered by the glomeruli and reabsorbed and catabolised by epithelial cells of the proximal tubule with only small amounts excreted in the urine. Serum cystatin C has been proposed as a new marker for renal function and is under evaluation for GFR estimation. Earlier studies suggested that cystatin C is a better alternative than Creatinine because it is not affected by muscle mass ([@ref2]; [@ref55]; [@ref68] and that makes it a better marker than Creatinine in children, elderly and in patients with reduced muscle mass ([@ref6]; [@ref18]). More research on cystatin C found that factors other than renal function (that also affect serum creatinine) do affect serum cystatin C but to a lesser extent ([@ref55]; [@ref70]). Wei et al found that serum cystatin C is raised with age but as GFR start to decrease, the effect of age would reduce with the decreasing GFR which then becomes the most influencing factor on cystatin C ([@ref91]). Two meta-analysis found cystatin C to be superior to creatinine as a marker for GFR ([@ref15]; [@ref74]). Several studies found cystatin C to be more accurate than creatinine in detecting early diabetic nephropathy ([@ref8]; [@ref12]; [@ref23]; [@ref36]; [@ref37]; [@ref54]; [@ref55]; [@ref67]; [@ref68]; [@ref73]; [@ref76]; [@ref91] See [Table 3](#T3){ref-type="table"}. Cystatin C can detect renal impairment in type 2 diabetic patients with normal albuminuria ([@ref29]). In addition, cystatin C has a role in identifying patients with CKD who are at higher risk for complication ([@ref61]; [@ref63] suggesting that cystatin C can predict patients at risk and warrant early referral. Very few studies looked into the role of cystatin C in detection of renal impairment in Malaysia ([@ref50]; [@ref97]). The high cost and limited availability of cystatin C test restricted its application in clinical practice. The introduction of certified reference material for cystatin C in 2010 intended to overcome the differences brought upon by using different calibrators and assays for cystatin C ([@ref20]). Recent guidelines from National Kidney Foundation recommend the use of cystatin C to validate the diagnosis of CKD in adults with GFR between 45-59 ml/min/1.73m^2^ and no other markers of kidney damage ([@ref4]). In light of this, future studies in Malaysia should evaluate the role of cystatin C in detecting early renal impairment and take into consideration the different ethnic groups when determining reference interval for cystatin C.

###### 

Comparison between Cystatin C and Creatinine in predicting early renal impairment

  1^st^ Author   population   Estimated GFR                          Measured GFR            Performance
  -------------- ------------ -------------------------------------- ----------------------- -----------------------------------
  ([@ref55]      52           Cockroft-Gault                         ^51^Cr-EDTA             Cystatin C superior to Creatinine
                                                                                             
  ([@ref68]      89           Cockroft-Gault                         ^51^Cr-EDTA             Cystatin C superior to Creatinine
                                                                                             
  ([@ref8]       123          NA                                     ^51^Cr-EDTA             Cystatin C superior to Creatinine
                                                                                             
  ([@ref67]      30           NA                                     Iothalamate clearance   Cystatin C superior to Creatinine
                                                                                             
  ([@ref23]      164          Cockroft-Gault and MDRD                ^51^Cr-EDTA             Cystatin C superior to Creatinine
                                                                                             
  ([@ref76]      460          Cockroft-Gault and MDRD                Iothalamate clearance   Cystatin C superior to Creatinine
                                                                                             
  ([@ref73]      124          Cockroft-Gault and MDRD                ^51^Cr-EDTA             Cystatin C superior to Creatinine
                                                                                             
  ([@ref12])     67           MDRD                                   ^51^Cr-EDTA             Cystatin C superior to Creatinine
                                                                                             
  ([@ref54]      48           Cockroft-Gault and MDRD                NA                      Cystatin C superior to Creatinine
                                                                                             
  ([@ref37]      289          Japanese modified MDRD                 NA                      Cystatin C superior to Creatinine
                                                                                             
  ([@ref29]      332          MDRD and CKD-EPI                       NA                      Cystatin C superior to Creatinine
                                                                                             
  ([@ref61]      234          MDRD and CKD-EPI 2009, 2012 equation   Iothalamate clearance   Cystatin C superior to Creatinine
                                                                                             
  ([@ref91]      800                                                 99mTc-DTPA              Cystatin C superior to Creatinine

4.3 Glomerular Filtration Rate (GFR) {#sec2-6}
------------------------------------

The GFR is regarded as the best indicator for renal function. Accurate GFR estimation is important for the diagnosis and management of kidney disease ([@ref83]). The gold standard method for measuring GFR using an exogenous filtration markers (e.g. inulin, iohexol, ^99m^diethylenetriaminepentaacetic acid, ^125^I-iothalamate and ^51^Cr-ethylenediaminetetraacetic acid) is expensive, time consuming and inconvenient for patients. Several equations have been developed to estimate GFR and serum creatinine is used in those equations ([@ref10]; [@ref34]; [@ref43] See [Table 4](#T4){ref-type="table"}. Nevertheless, serum creatinine has many limitations because it is affected by factors other than renal function, such as age, gender, race, muscle weight, diet and certain medications ([@ref42]; [@ref55]; [@ref45]). Moreover, kidney function can be reduced up to 50% and serum creatinine is still within normal range. [@ref4]). The majority of GFR estimating equations were developed in the western countries, and despite the fact that Asia ranks high for prevalence of end stage renal disease, Asian countries do not have a unified GFR estimation equation.

###### 

GFR Estimating Equations

  Year   Equation                                                  
  ------ --------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1976   Cockroft-Gault([@ref10])                                  \[(140-Age)×Weight\](72×SCr)×0.85 (if female)
                                                                   
  2002   4-variable MDRD([@ref4])                                  186×(SCr)^-1.154^×(Age)^-0.203^×(0.742)(if female)
                                                                   
  2006   Re-expressed MDRD for standardized Creatinine ([@ref45]   175×(SCr)^-1.154^×(Age)^-0.203^×(0.742) (if female)×(1.212)(if black)
                                                                   
  2006   Chinese modified MDRD([@ref48]                            (4-variable MDRD)×1.233
                                                                   
  2007   Japanese modified MDRD([@ref27]                           (4-variable MDRD)×0.741
                                                                   
  2009   Japanese modified MDRD([@ref52]                           (re-expressed MDRD)×0.808
                                                                   
  2011   Thai modified MDRD([@ref69]                               (re-expressed MDRD)×1.129
                                                                   
  2011   Thai eGFR formula ([@ref69]                               375.5×(SCr)^-0.848^×Age ^-0.364^×0.712 (if female)
                                                                   
  2009   CKD-EPI creatinine([@ref46]                               141×min(SCr/k,1)^α^×max(SCr/k,1)^-1.209^×0.993^age^\[×1.018 if female\]×\[1.159 if black\], where SCr is serum creatinine, k is 0.7 if female and 0.9 if male, α is -0.329 if female and -0.411 if male, min is the minimum of SCr/k or 1, and Max is the maximum of SCr/k or 1.
                                                                   
  2012   CKD-EPI cystatin C([@ref28]                               133×min(Scys/0.8,1)^-0.499^×max(Scys/0.8,1)^-1.328^×0.996^age^\[×0.932 if female\], Scys is Serum Cystatin C, min indicates the minimum of Scr/k or 1, and max indicates the maximum of Scys/k or1.
                                                                   
  2012   CKD-EPI creatinine-cystatin C ([@ref28]                   135×min(SCr/k,1)^α^×max(SCr/k,1)^-0.601^×min(Scys/0.8,1)^-0.375^×max max(Scys/0.8,1)^-0.711^×0.995^age^\[×0.969 if female\] ×1.08 if black, where SCr is serum creatinine, SCys is serum cystatin C, k is 0.7 if female and 0.9 if male, α is -0.248 if female and -0.207 if male, min indicate the minimum of SCr/k or 1, and max indicate the maximum of SCr/k or 1.

### 4.3.1 GFR Estimation by the MDRD Equation {#sec3-4}

The MDRD equation was introduced in 1999 and is used to estimate GFR. The equation was developed in 1628 Caucasians and African Americans patients with impaired kidney function ([@ref43]). The equation has been re-expressed in 2006 for standard creatinine to improve its accuracy ([@ref45]). The standardization of serum creatinine came as a big step to overcome the variability caused by using different measures for serum creatinine. The MDRD equation is used in Asia to estimate GFR, but being dependant on creatinine does not make it an ideal equation. Creatinine is influenced by muscle mass and Asian are different from Caucasian and from each other in their body mass index/body fat % relationship ([@ref14]; [@ref92]). In China the MDRD equation was modified with a racial coefficient ([@ref48]), also in Japan ([@ref27]; [@ref52] and in Thailand ([@ref69]). See [Table (3](#T3){ref-type="table"}). Adding a racial coefficient led to better GFR estimation but there was a difference between the Chinese and Japanese coefficient. The variation could be attributed to methodological rather than ethnic difference because the reference GFR measurement and creatinine measurements were different in both studies ([@ref22]; [@ref75]). In Malaysia, the MDRD equation was adopted without modification.

### 4.3.2 GFR estimation by The CKD-EPI Creatinine Equation {#sec3-5}

The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) group introduced a new equation in 2009. The CKD-EPI creatinine equation was developed in 8254 patients and validated in 3896 patients including patients with and without kidney disease ([@ref46]). The CKD-EPI equation retained the precision and accuracy of the MDRD equation at GFR \< 60 ml/min/1.73m^2^, showed less bias and improved precision at GFR\>60ml/min/1.73m^2^ ([@ref81]). The MDRD equation was known for underestimating GFR higher than 60ml/min/1.73m^2^ ([@ref13]; [@ref72]). The CKD-EPI equation is reportedly more accurate and resulted in lower prevalence of estimated GFR\< 60 ml/min/1.73m^2^. Patients who were reclassified to higher GFR using the CKD-EPI equation had lower risk of death and less likely to have CKD risk factors or co-morbid conditions based on data extracted from longitudinal studies ([@ref38]; [@ref53]; [@ref78]; [@ref83]; [@ref86]; [@ref93]) See [Table 5](#T5){ref-type="table"}. Although one study reported that the MDRD equation was more appropriate for risk stratification in 85 year old patients ([@ref94]). The CKD-EPI equation was validated in different population and was found to have lower bias and more accuracy compared to the MDRD equation ([@ref16]; [@ref30]; [@ref32]; [@ref84]; [@ref88]). Currently the reporting limit for estimating GFR with the MDRD equation is set at 60ml/min/1.73m^2^ and GFR in the range of 60-90ml/min/1.73m^2^ (although being CKD stage 1-2) falls under GFR \>60ml/min/1.73m^2^ ([@ref13]). But with CKD-EPI equation the reporting limit has been increased to 90ml/min/1.73m^2^ ([@ref33]). In Asian countries, namely China, Japan and Korea, adding an ethnic coefficient to the CKD-EPI equation led to better performance ([@ref25]) ([@ref16]; [@ref30]). In Singapore, a multiracial country similar to Malaysia, the CKD-EPI creatinine equation did not need an ethnic coefficient because the derived coefficients were very close to each other ([@ref88]). In Malaysia, the CKD-EPI equation is yet to be validated. Population based studies should evaluate the performance of the new equation and take into account the aborigines and whether an ethnic coefficient is necessary.

###### 

Comparison between the MDRD And CKD-EPI Equation For Risk Stratification And CKD Prevalence

  1^st^ Author   Study Population                           Years of follow up   Performance of CKD-EPI equation to estimate GFR                       Percentage of CKD patients Reclassified using CKD-EPI          Prevalence of CKD using CKD-EPI equation (compare to MDRD)
  -------------- ------------------------------------------ -------------------- --------------------------------------------------------------------- -------------------------------------------------------------- ------------------------------------------------------------
  ([@ref93]      11,247                                     7.5                  CKD-EPI improve risk stratification                                   4.54% of CKD grade 3a to CKD                                   13.4% to 11.5%
                                                                                                                                                                                                                      
  ([@ref83])     116,321                                    3.7                  CKD-EPI improve risk stratification                                   24.4% of CKD grade 3a to higher GFR                            16.8% to 14.3%
                                                                                                                                                                                                                      
  ([@ref78]      16,010                                     18                   CKD-EPI improve risk stratification                                   19.4% of CKD grade 3 to higher GFR                             45.6% to 28.8%
                                                                                                                                                                                                                      
  ([@ref86]      2,823 type 2 diabetic                      6                    CKD-EPI improve risk stratification for all cause mortality and CVD   NA                                                             22% to 20.2
                                                                                                                                                                                                                      
  ([@ref53]      13,905 middle age without history of CVD   16.9                 CKD-EPI improve risk stratification                                   44.9% of CKD grade1&2 and 43.5% of CKD grade 3 to higher GFR   From 2.5% to 1.4%

### 4.3.3 GFR Estimation by Cystatin C Equation {#sec3-6}

Cystatin C has been proposed as a new marker to detect early renal function decline in the absence of albuminuria, predict renal impairment when GFR is still normal or elevated and also has a role as risk predictor to warrant early referral. Serum cystatin C is also affected by non-renal factors, though to a lesser extent compared to serum creatinine. Several cystatin C based equations have been developed to estimate GFR. Some of those equations incorporated both cystatin C and creatinine and they performed fairly well ([@ref49]). Cystatin C based equations improved GFR estimates in CKD patients ([@ref41]; [@ref47]; [@ref73]; [@ref76]). In 2012 The CKD-EPI group introduced GFR estimating equation that incorporates cystatin C and one that incorporates both cystatin C and creatinine. The two equations were developed in 5352 participant from 13 studies and the combination equation (that includes cystatin C and creatinine) performed better than equations based on either of them alone, suggesting that errors due to non renal determinants of creatinine and cystatin C are smaller in equation that combines both of them. The researchers recommend that cystatin C should not replace creatinine, instead, an equation combining both of them provides more accurate GFR estimates for certain groups ([@ref28]). Another comparison between the new CKD-EPI equation based on cystatin C alone and a combination of cystatin C and creatinine in kidney transplant recipient also found that both equation performed better than the CKD-EPI creatinine equation ([@ref51]). In a meta-analysis of 11 general population studies (including a total of 90,750 participants) and 5 cohort on CKD patients (including a total of 2960 participants) found that estimating GFR using the CKD-EPI cystatin C equation and the CKD-EPI cystatin C and creatinine equation strengthened the association between GFR categories and the risk of death and end stage renal failure across diverse populations. The study also found that 42% of participants with GFR 45-59ml/min/1.73m^2^ using the creatinine based GFR where reclassified to GFR \> 60ml/min/1.73m^2^ using the cystatin C equation. Patients who were reclassified to higher GFR had 34% reduction in risk of death and 80% reduction in risk of end stage renal disease ([@ref79]). In Singapore, the CKD EPI equation 2012 (using both cystatin C and creatinine) were evaluated and found that a combination of both markers increase precision without having to add an ethnic coefficients ([@ref87]). Currently, the National Kidney Foundation recommends the use of cystatin C based equation to estimate GFR whenever cystatin C is ordered ([@ref4]).

5. Conclusion and Recommendation {#sec1-5}
================================

Screening for CKD in Malaysia is based on creatinine and albuminuria. Creatinine is known for its limitation, being affected by non-renal factors and rising only after substantial kidney damage has occurred. The GFR should be reported by laboratories whenever serum creatinine is ordered, so as not to miss patients who have a declining GFR and a seemingly normal creatinine. The MDRD equation is currently used (without ethnic coefficient) to estimate GFR, but being dependant on creatinine puts at a disadvantage. The new CKD-EPI equation is a promising new measure for GFR estimation having performed well compared to the MDRD equation. This needs validation in multiethnic Malaysian population. Population based study should be undertaken to determine whether an ethnic coefficient is needed for the new equation.

Albuminuria may not be as sensitive as a marker as previously thought. Recent studies show that GFR decline can occur in the absence of albuminuria. Research should be undertaken in Malaysia to further evaluate the role of albuminuria in detecting early decline in GFR. Cystatin C was proposed as a new marker for renal impairment. Cystatin C is shown to be superior to creatinine in detecting early renal function decline. This needs further evaluation in Malaysia to determine the exact role of cystatin C as compared to other CKD markers. Reference interval for cystatin C should be established for Chinese, Indians and Malays in Malaysia.
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